BAKER BROS. ADVISORS LP Q2 2017 Filing
Filed August 14, 2017
Portfolio Value
$11.4T
Holdings
120
Report Date
Q2 2017
Filing Type
13F-HR
All Holdings (120 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $911.0M | 0.01% | |
| 102 | —Palatin Technologies, Inc. | 2,050,000 | $882.0M | 0.01% | |
| 103 | XLRNAcceleron Pharma Inc. | 28,765 | $874.0M | 0.01% | |
| 104 | CRBPEURCorbus Pharmaceuticals Holdings, Inc. | 130,129 | $820.0M | 0.01% | |
| 105 | —Affimed N.V. | 400,000 | $820.0M | 0.01% | |
| 106 | FLGTFulgent Genetics, Inc. | 125,000 | $799.0M | 0.01% | |
| 107 | DVAXDynavax Technologies Corporation | 75,000 | $724.0M | 0.01% | |
| 108 | I9DNArbutus Biopharma Corporation | 180,582 | $650.0M | 0.01% | |
| 109 | CMRXEURChimerix, Inc. | 115,216 | $628.0M | 0.01% | |
| 110 | —BioDelivery Sciences International, Inc. | 210,021 | $588.0M | 0.01% | |
| 111 | —Five Prime Therapeutics, Inc. | 19,247 | $580.0M | 0.01% | |
| 112 | —Bioverativ Inc. | 8,249 | $496.0M | 0.00% | |
| 113 | CCXIEURChemoCentryx, Inc. | 49,064 | $459.0M | 0.00% | |
| 114 | —Proteon Therapeutics, Inc. | 298,591 | $455.0M | 0.00% | |
| 115 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $449.0M | 0.00% | |
| 116 | —BioPharmX Corporation | 598,758 | $287.0M | 0.00% | |
| 117 | —Ritter Pharmaceuticals, Inc. | 400,000 | $220.0M | 0.00% | |
| 118 | —Tenax Therapeutics, Inc. | 132,974 | $98.0M | 0.00% | |
| 119 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $82.0M | 0.00% | |
| 120 | —BioTime, Inc. | 20,084 | $7.0M | 0.00% |
PreviousPage 2 of 2